149.85
0.60%
+0.90
アフターアワーズ:
149.85
Johnson & Johnson (JNJ) 最新ニュース
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
Zacks Investment Research
3 Top Dividend Stocks to Maximize Your Retirement Income
Zacks Investment Research
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Zacks Investment Research
What Is the Dividend Payout for Johnson & Johnson Stock?
The Motley Fool
Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates
Zacks Investment Research
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
The Motley Fool
The Zacks Analyst Blog Highlights Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips
Zacks Investment Research
Johnson & Johnson's TARIS Platform - Goldman Sachs Outlines Potential For The Bladder Cancer Therapy
Benzinga
Q1 Earnings Season Scorecard and Fresh Analyst Reports for Tesla, JNJ & Netflix
Zacks Investment Research
A Look at Pharma ETFs Post Q1 Earnings
Zacks Investment Research
5 Relatively Secure And Cheap Dividend Stocks To Invest In - May 2024
Seeking Alpha
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Zacks Investment Research
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
Zacks Investment Research
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Zacks Investment Research
3 Dividend Growth Stocks that Just Raised Their Payouts
The Motley Fool
5 Expected Dividend Increases In May 2024
Seeking Alpha
Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market
Benzinga
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
Zacks Investment Research
3 No-Brainer Stocks to Buy With $200 Right Now
The Motley Fool
Johnson & Johnson Is a King of Dividend Safety
The Motley Fool
2 Top Growth Stocks to Buy Right Now and Hold Forever
The Motley Fool
Better Dividend Stock: AbbVie or Johnson & Johnson?
The Motley Fool
Johnson & Johnson Stock: Buy, Sell, or Hold?
The Motley Fool
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
Zacks Investment Research
Are You Looking for a High-Growth Dividend Stock?
Zacks Investment Research
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks Investment Research
5 Stocks in Focus on Their Recent Dividend Hike
Zacks Investment Research
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
The Zacks Analyst Blog Highlights KB Home, Interactive Brokers Group, Qualcomm and Johnson & Johnson
Zacks Investment Research
These Are the 10 High-Profile Stocks U.S. Politicians Have Gravitated to Most Over the Last 3 Years
The Motley Fool
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
The Motley Fool
4 Stocks to Watch on Their Recent Dividend Hikes
Zacks Investment Research
Not A Millionaire? No Problem! Here's A 10-Stock Portfolio To Retire Comfortably
Seeking Alpha
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Zacks Investment Research
10 High-Yield Dividend Aristocrats Perfect For An Uncertain Market
Seeking Alpha
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
Zacks Investment Research
The Zacks Analyst Blog Highlights NVIDIA, Alphabet, Johnson & Johnson, Broadridge Financial and Textron
Zacks Investment Research
Top Stock Reports for NVIDIA, Alphabet & Johnson & Johnson
Zacks Investment Research
Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About Future
Benzinga
Johnson & Johnson Analysts Cut Their Forecasts After Q1 Results
Benzinga
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
Zacks Investment Research
Company News for Apr 17, 2024
Zacks Investment Research
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga
Why Johnson & Johnson Stock Got Tossed by the Market Today
The Motley Fool
Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript
The Motley Fool
Stocks Grapple With Geopolitical Pressures, Gold Eyes $2,400, Bitcoin Falls Below $62,000: What's Driving Markets Tuesday?
Benzinga
Building Permits Come in Lower Than Expected
Zacks Investment Research
J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft
Zacks Investment Research
Housing Numbers Shrink as Q1 Earnings Heat Up: BAC, JNJ, UNH
Zacks Investment Research
Johnson & Johnson (JNJ) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks Investment Research
大文字化:
|
ボリューム (24 時間):